Your browser doesn't support javascript.
loading
Economic evaluation of third-line neratinib plus capecitabine versus lapatinib plus capecitabine with HER2+ metastatic breast cancer.
Ren, Lanqi; Ren, Ning; Zheng, Yu; Yang, Yibei; Xu, Qiaoping.
Afiliación
  • Ren L; Fourth Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
  • Ren N; Fourth Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
  • Zheng Y; Second Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
  • Yang Y; Fourth Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
  • Xu Q; Department of Clinical Pharmacology, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People's Hospital, Cancer Center, Zhejiang University School of Medicine, Hangzhou, China.
Front Oncol ; 13: 1221969, 2023.
Article en En | MEDLINE | ID: mdl-37621688
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Health_economic_evaluation / Prognostic_studies Idioma: En Revista: Front Oncol Año: 2023 Tipo del documento: Article País de afiliación: China
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Health_economic_evaluation / Prognostic_studies Idioma: En Revista: Front Oncol Año: 2023 Tipo del documento: Article País de afiliación: China